Cancer patients to continue promising treatments in major extension trial
Disease control
Not yet recruiting
This long-term extension study offers continued access to several cancer drugs—including cabozantinib, atezolizumab, and nivolumab—for up to 5,000 patients who benefited from them in earlier Exelixis-sponsored trials. The study focuses on monitoring safety and ongoing clinical be…
Phase: PHASE3 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC